Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …
CAR-T cell therapy: current limitations and potential strategies
RC Sterner, RM Sterner - Blood cancer journal, 2021 - nature.com
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
Patient-derived xenograft models in cancer therapy: technologies and applications
Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …
into immunocompromised or humanized mice, have shown superiority in recapitulating the …
CAR T cells in solid tumors: challenges and opportunities
F Marofi, R Motavalli, VA Safonov… - Stem cell research & …, 2021 - Springer
Background CARs are simulated receptors containing an extracellular single-chain variable
fragment (scFv), a transmembrane domain, as well as an intracellular region of …
fragment (scFv), a transmembrane domain, as well as an intracellular region of …
Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety
NA Vitanza, AL Wilson, W Huang, K Seidel, C Brown… - Cancer discovery, 2023 - AACR
Diffuse intrinsic pontine glioma (DIPG) remains a fatal brainstem tumor demanding
innovative therapies. As B7-H3 (CD276) is expressed on central nervous system (CNS) …
innovative therapies. As B7-H3 (CD276) is expressed on central nervous system (CNS) …
Targeting STAT3 in cancer immunotherapy
S Zou, Q Tong, B Liu, W Huang, Y Tian, X Fu - Molecular cancer, 2020 - Springer
As a point of convergence for numerous oncogenic signaling pathways, signal transducer
and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune …
and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune …
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
KM Cappell, JN Kochenderfer - Nature reviews Clinical oncology, 2021 - nature.com
Chimeric antigen receptors (CARs) are engineered proteins designed to target T cells to
cancer cells. To effectively activate the T cells in which they are expressed, CARs must …
cancer cells. To effectively activate the T cells in which they are expressed, CARs must …
Senolytic CAR T cells reverse senescence-associated pathologies
Cellular senescence is characterized by stable cell-cycle arrest and a secretory program that
modulates the tissue microenvironment,. Physiologically, senescence serves as a tumour …
modulates the tissue microenvironment,. Physiologically, senescence serves as a tumour …
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
T Yan, L Zhu, J Chen - Experimental Hematology & Oncology, 2023 - Springer
The past decade has witnessed ongoing progress in immune therapy to ameliorate human
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …